NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

CalciMedica Tumbles as Safety Concerns Halt Trial of Kidney Injury Drug

CalciMedica discontinues Phase 2 KOURAGE trial for acute kidney injury drug Auxora following safety concerns raised by independent committee monitoring the study.

CalciMedica Tumbles as Safety Concerns Halt Trial of Kidney Injury Drug
Credit: CalciMedica
Already have an account? Sign in.
01/28/2026 · 10:08 AM
CALC
/ Don’t stop at just one post.

Related↓

FDA Alignment De-Risks CalciMedica’s Auxora Path in Acute Pancreatitis
07/29/2026 · 11:28 AM

FDA Alignment De-Risks CalciMedica’s Auxora Path in Acute Pancreatitis

FDA aligns with CalciMedica on Auxora Phase 2b endpoints for acute pancreatitis, de-risking the path to registration.

/ Subscriber only
/ Read more

Feed↓

AI Neocloud Nscale Targets $3 Billion IPO, Backed by $51 Billion in Contracted Revenue
Featured/ 08/21/2026 · 2:45 PM

AI Neocloud Nscale Targets $3 Billion IPO, Backed by $51 Billion in Contracted Revenue

Nvidia, Dell and Nokia-backed Nscale seeks up to $3B U.S. IPO.

/ Subscriber only
Tesla Shares Surge on Major Robotaxi Approvals and Upcoming Cybercab Launch
Featured/ 08/21/2026 · 2:31 PM

Tesla Shares Surge on Major Robotaxi Approvals and Upcoming Cybercab Launch

Tesla receives approval to deploy up to 5,000 robotaxis in Clark County and prepares to launch its purpose-built Cybercab in Austin, Texas.

/ Subscriber only
Solid Biosciences and Stoke Therapeutics Get Fresh Bullish Analyst Backing with Big Upside Targets
08/21/2026 · 12:20 PM

Solid Biosciences and Stoke Therapeutics Get Fresh Bullish Analyst Backing with Big Upside Targets

Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe